在ACS中短暂的DAPT后,提卡格勒单疗法:是时候将理论转化为实践了
Mattia Galli1, Sebastiano Sciarretta2
1Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Med (New York, N.Y.)
|December 14, 2024
概括
目前的指导方针建议在急性冠状动脉综合征 (ACS) 后进行12个月的双重抗血小板治疗 (DAPT). 然而,试验可能缺乏证实高风险患者的益处的能力,需要进一步分析.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 基于证据的医学基于证据的医学.
背景情况:
- 目前的指导方针建议在急性冠状动脉综合征 (ACS) 后进行12个月的双重抗血小板治疗 (DAPT).
- 试验功率的限制可能会阻碍缺血终点的检测,特别是在高风险的ACS亚组中,如ST升高ACS.
- 对个体患者数据的元分析对于解决这些局限性至关重要.
研究的目的:
- 评估急性冠状动脉综合征 (ACS) 患者的DAPT持续时间的疗效和安全性.
- 具体评估高风险ACS子组的结果,包括ST-升高ACS.
- 为了利用个人患者数据的元分析来产生可靠的证据.
主要方法:
- 进行相关临床试验的个人患者数据元分析.
- 分析硬性缺血终点和出血事件.
- 基于患者风险概况的分层结果,包括ST升高ACS.
主要成果:
- 试验功率不足可能会影响对最佳DAPT持续时间的最终结论.
- 高风险的ACS患者,特别是ST升高ACS患者,需要仔细考虑.
- 单个患者数据的元分析为子组分析提供了增强的统计能力.
结论:
- 根据可靠的元分析数据,可能需要对12个月的DAPT建议进行重新评估.
- 专注于高风险ACS人群的进一步研究至关重要.
- 对个体患者数据的元分析对于完善ACS管理中的DAPT策略至关重要.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
467
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
453
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
453
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
902
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
902
Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
775
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
775


